Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).
about
Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report.Conformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and SildenafilPharmacotherapy of erectile dysfunction: focus on cardiovascular safety.Acute haemodynamic response in relation to plasma vardenafil concentrations in patients with pulmonary hypertensionPotency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor.PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model.Pharmacological modulation of cytotoxicity and cellular uptake of anti-cancer drugs by PDE5 inhibitors in lung cancer cellsSystemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil.Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates.The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension.Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer.High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension.Acute vasodilator response to vardenafil and clinical outcome in patients with pulmonary hypertension.Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects.
P2860
Q24813821-16A00312-CD08-4BFB-A7B4-387D16AAECF2Q27648887-EF5C6C36-E796-4491-9A04-779844FF7E08Q36150572-716A9484-2827-4737-AE80-D162535F7644Q36468138-7A31C8C1-19ED-4AD8-8873-745E514E6947Q36572595-730764AA-F9A4-4AEB-ADF7-B3E1DDE57241Q37076589-A414E5AE-62FA-4914-8D31-12670ED88441Q37395863-0AC255ED-BA24-431B-8FBE-0DD8F8F5C339Q39652258-036D1F8B-0400-43DA-961A-7BB790D79909Q40352545-7883A24C-9F03-4D47-82C0-4D56479DF5FEQ41039819-DD69485C-8283-4B9F-ADB1-B1073B127D5EQ43712141-DD924675-11D2-4773-A7E6-63A7F8E36A7FQ47138288-300C303F-1BFB-4AB2-AE57-98A808FEFD38Q50793400-F19D569B-AD64-4CEE-9F1A-8FF92139344FQ50853728-C9F1D262-205C-48BC-BF43-FB43D4EF533EQ51809623-AC1187ED-1E09-4BBE-83E3-9DE9D39FDC98
P2860
Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Vardenafil: structural basis f ...... ic phosphodiesterase-5 (PDE5).
@ast
Vardenafil: structural basis f ...... ic phosphodiesterase-5 (PDE5).
@en
Vardenafil: structural basis f ...... P-specific phosphodiesterase-5
@nl
type
label
Vardenafil: structural basis f ...... ic phosphodiesterase-5 (PDE5).
@ast
Vardenafil: structural basis f ...... ic phosphodiesterase-5 (PDE5).
@en
Vardenafil: structural basis f ...... P-specific phosphodiesterase-5
@nl
prefLabel
Vardenafil: structural basis f ...... ic phosphodiesterase-5 (PDE5).
@ast
Vardenafil: structural basis f ...... ic phosphodiesterase-5 (PDE5).
@en
Vardenafil: structural basis f ...... P-specific phosphodiesterase-5
@nl
P2093
P1476
Vardenafil: structural basis f ...... ic phosphodiesterase-5 (PDE5).
@en
P2093
Alfreda Beasley
Jackie D Corbin
Mitsi A Blount
Sharron H Francis
P304
P356
10.1016/J.NEUINT.2004.03.016
P577
2004-11-01T00:00:00Z